25 hours ago Oysterpoint Patient Portal This portal allows our patients to have 24/7/365 access to their medical records here, at Oyster Point Family Practice. It also has many other features and … >> Go To The Portal
This portal allows our patients to have 24/7/365 access to their medical records here, at Oyster Point Family Practice. It also has many other features and benefits available to our patients, some of which are listed below. Setup healthcare reminders for medication refills or scheduling of necessary tests or appointments
The Patient Portal has multiple features and benefits to help you manage your health all from the comfort of your own home or on the go with the InteliChart Patient Portal mobile app. Registering for the portal is quick, easy and secure.
By registering for the Patient Portal, you consent to receive communications from us electronically.
While the previous Patient Portal will still be accessible to retrieve your past lab results or messages, you will not be able to communicate with your TPMG provider through that Patient Portal. If you have any questions about registering for the new Patient Portal, contact your health care provider’s office.
(Nasdaq: OYST), ("Oyster Point Pharma" or "the Company") a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that results from the multicenter, randomized, double-masked, vehicle-controlled Phase 3 clinical trial (The ONSET-2 study) of TYRVAYATM Nasal Spray (varenicline solution)
To access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International). The conference ID number is 9384288.
Our lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptors (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). The company is also developing other product candidates for diseases of the ocular surface and beyond.
PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) Annual Meeting 2021 being held in New Orleans, LA November 12th – 15th, 2021. “The American Academy of Ophthalmology is the world’s
The Company submitted its 505 (b) (2) NDA to the FDA for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease on December 17, 2020.
Jill joined Oyster Point from Bristol Myers Squibb, post-acquisition of Celgene Corporation where she was Vice President, Head of Legal for the Inflammation & Immunology global franchise. Prior to joining Celgene, Jill held various positions of increasing responsibility at Novartis, including senior leadership roles in legal and compliance at Novartis Pharmaceuticals Corporation and Novartis Consumer Health. Jill has developed a track record for being an integral business partner while building key legal and compliance functions necessary to support and sustain growing and diversifying businesses. Jill has worked extensively on matters related to product development, marketing approval and commercialization, including product launches across multiple therapeutic areas. Her experience also spans corporate governance, corporate transactions, IP, litigation and investigations. Prior to joining the pharmaceutical industry, Jill was an Assistant U.S. Attorney for the District of New Jersey and was a litigation associate at the law firm of Davis Polk & Wardwell. She holds a J.D. from Wake Forest University, School of Law and a B.S. in Finance from Boston College.
OC-01 (varenicline) nasal spray is an investigational new drug and has not been approved for any use in any country. The safety and efficacy of OC-01 (varenicline) nasal spray have not previously been established.
At your first visit with us at Oyster Point Oral And Facial Surgery, our team will work directly with you to establish your needs, goals and ideal treatment methods. The information below will help you prepare for this visit, including necessary forms and what you can expect from your initial consultation with our team.
Your first visit with us will consist of a consultation to go over your diagnosis and treatment options. On some occasions, surgery can be performed on the same day as this initial consultation. However, these types of appointments must be planned ahead of time.
For your convenience, we accept Visa, MasterCard, Discover, American Express, Care Credit and Greensky Solutions.
At Oyster Point Oral & Facial Surgery, we believe that patients deserve the best, and we work hard to provide exactly that to every patient who comes through our doors. Simply fill out the form below and our team will contact you to schedule your appointment at our office. We look forward to meeting you!
At Tidewater Physicians Multispecialty Group (TPMG), our four areas of primary care include family medicine, geriatric medicine, internal medicine, and pediatric medicine. Learn more about the different areas of TPMG Primary Care.
To self-register, obtain a registration PIN by contacting your health care providers’ office. Your PIN will be sent via your preferred method of communication, either email or text message.
In May 2020, TPMG moved to a new Patient Portal. If you utilized the TPMG Patient Portal prior to May 2020, hosted by NextMD, and have not yet registered for our new Patient Portal, hosted by InteliChart, please contact your health care provider’s office to request a registration PIN.
While the previous Patient Portal will still be accessible to retrieve your past lab results or messages, you will not be able to communicate with your TPMG provider through that Patient Portal. If you have any questions about registering for the new Patient Portal, contact your health care provider’s office.